Nestle, Zydus, Abbott face India scrutiny over claims on children's products

By Reuters News

BENGALURU, Oct 21 (Reuters) - India's food safety regulator issued notices to Nestle India NEST.NS, Zydus Wellness ZYDS.NS, Abbott Healthcare and others on Wednesday over promotional claims involving products for infants and children that it said breached rules.

Nestle India, Zydus Wellness and Abbott did not immediately respond to requests for comment outside regular business hours.

The action comes days after the regulator proposed banning the addition of sucrose and fructose to foods for infants up to six months old, as India steps up scrutiny of food safety and pushes for front-of-pack warning labels, rattling the country's more than $100 billion packaged food industry.


  • The Food Safety and Standards Authority of India said it issued notices over products including Complan, Lactogen Pro 1 Powder, NAN Excella Pro Stage 1 and infant milk substitutes.

  • The regulator asked Nestle India to provide evidence supporting claims about digestive and immune-system benefits for its Lactogen Pro 1 Powder and NAN Excella Pro Stage 1 infant formula products.

  • Zydus Wellness was asked to provide scientific justification for claims promoting its Complan children's drink, including the tagline "grow taller, faster. clinically proven 2X growth."

  • FSSAI also issued notices to social media influencer Ira Fathima and companies including Abbott Healthcare and Nestle India over an Instagram reel promoting infant milk substitutes.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.